Latest News

  • Exosomes Start To Prove Their Worth in Cancer Management

    Diagnostics World News | Massachusetts General Hospital has developed liquid biopsy technologies to do high-throughput exosome protein profiling and point-of-care exosome analysis.

    Nov 8, 2019
  • Electrokinetic Chip Quickly Deep-Dives For Cancer Clues

    Diagnostics World News | Exosomes are promising targets for liquid biopsy diagnostics, but they’ve proven difficult to quickly capture and analyze. Oregon Health & Science University scientists are helping to overcome this hurdle with an alternating current electrokinetic microarray chip that integrates the isolation and analysis of exosomes and cell-free DNA biomarkers from a drop of blood.

    Nov 6, 2019
  • New-To-Market Tales of Two POC Diagnostic Products

    Diagnostics World News | Companies looking to commercialize rapid diagnostics technologies might want to borrow from the playbook of those who successfully brought their point-of-care (POC) products to market.

    Nov 5, 2019
  • Precision Oncology Facing Inequities and Acceptance Issues

    Diagnostics World News | Precision medicine promises treatment strategies tailored to individual patient characteristics and tumor biology. But improved health outcomes won’t happen without access to healthcare and molecular testing, which can differ substantially by geography and even within individual countries.

    Nov 1, 2019
  • Illumina, QIAGEN, Optibrium, and More: News From October 2019

    Diagnostics World News | October featured news, products, and partnerships from around the diagnostics community from numerous companies, universities, and organizations, including Illumina, QIAGEN, Optibrium, and more.

    Oct 31, 2019
  • Overcoming Obstacles With Liquid Biopsies

    Diagnostics World News | The value of liquid biopsies in precision medicine, particularly for managing cancers where tissue samples from tumors and metastatic sites are hard if not impossible to obtain, is a major topic of conversation, as tests that look for circulating tumor cells and circulating tumor DNA are enjoying a "resurgence" in clinical trials.

    Oct 29, 2019